These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 15832172)
1. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Dilley J; Reddy S; Ko D; Nguyen N; Rojas G; Working P; Yu DC Cancer Gene Ther; 2005 Aug; 12(8):715-22. PubMed ID: 15832172 [TBL] [Abstract][Full Text] [Related]
2. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Chen Y; DeWeese T; Dilley J; Zhang Y; Li Y; Ramesh N; Lee J; Pennathur-Das R; Radzyminski J; Wypych J; Brignetti D; Scott S; Stephens J; Karpf DB; Henderson DR; Yu DC Cancer Res; 2001 Jul; 61(14):5453-60. PubMed ID: 11454691 [TBL] [Abstract][Full Text] [Related]
3. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637 [TBL] [Abstract][Full Text] [Related]
4. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Small EJ; Carducci MA; Burke JM; Rodriguez R; Fong L; van Ummersen L; Yu DC; Aimi J; Ando D; Working P; Kirn D; Wilding G Mol Ther; 2006 Jul; 14(1):107-17. PubMed ID: 16690359 [TBL] [Abstract][Full Text] [Related]
5. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models. Li Y; Idamakanti N; Arroyo T; Thorne S; Reid T; Nichols S; VanRoey M; Colbern G; Nguyen N; Tam O; Working P; Yu DC Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8845-55. PubMed ID: 16361574 [TBL] [Abstract][Full Text] [Related]
6. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615 [TBL] [Abstract][Full Text] [Related]
7. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667 [TBL] [Abstract][Full Text] [Related]
8. Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma. Lamfers ML; Idema S; Bosscher L; Heukelom S; Moeniralm S; van der Meulen-Muileman IH; Overmeer RM; van der Valk P; van Beusechem VW; Gerritsen WR; Vandertop WP; Dirven CM Clin Cancer Res; 2007 Dec; 13(24):7451-8. PubMed ID: 18094429 [TBL] [Abstract][Full Text] [Related]
9. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo. Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558 [TBL] [Abstract][Full Text] [Related]
10. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196 [TBL] [Abstract][Full Text] [Related]
11. Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter. Hakkarainen T; Rajecki M; Sarparanta M; Tenhunen M; Airaksinen AJ; Desmond RA; Kairemo K; Hemminki A Clin Cancer Res; 2009 Sep; 15(17):5396-403. PubMed ID: 19706820 [TBL] [Abstract][Full Text] [Related]
12. Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. Cowen D; Salem N; Ashoori F; Meyn R; Meistrich ML; Roth JA; Pollack A Clin Cancer Res; 2000 Nov; 6(11):4402-8. PubMed ID: 11106260 [TBL] [Abstract][Full Text] [Related]
13. Double E1B 19 kDa- and E1B 55 kDa-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect. Kim J; Kim PH; Yoo JY; Yoon AR; Choi HJ; Seong J; Kim IW; Kim JH; Yun CO Gene Ther; 2009 Sep; 16(9):1111-21. PubMed ID: 19494843 [TBL] [Abstract][Full Text] [Related]
14. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy. Li X; Liu YH; Lee SJ; Gardner TA; Jeng MH; Kao C Clin Cancer Res; 2008 Jan; 14(1):291-9. PubMed ID: 18172281 [TBL] [Abstract][Full Text] [Related]
15. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044 [TBL] [Abstract][Full Text] [Related]
16. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145 [TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876 [TBL] [Abstract][Full Text] [Related]
18. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy. Su C; Na M; Chen J; Wang X; Liu Y; Wang W; Zhang Q; Li L; Long J; Liu X; Wu M; Fan X; Qian Q Mol Cancer Res; 2008 Apr; 6(4):568-75. PubMed ID: 18344493 [TBL] [Abstract][Full Text] [Related]
19. E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer. Fukuda K; Abei M; Ugai H; Kawashima R; Seo E; Wakayama M; Murata T; Endo S; Hamada H; Hyodo I; Yokoyama KK Cancer Gene Ther; 2009 Feb; 16(2):126-36. PubMed ID: 18818710 [TBL] [Abstract][Full Text] [Related]
20. Oncolytic adenovirus armed with human papillomavirus E2 gene in combination with radiation demonstrates synergistic enhancements of antitumor efficacy. Wang W; Xia X; Wang S; Sima N; Li Y; Han Z; Gao Q; Luo A; Li K; Meng L; Zhou J; Wang C; Shen K; Ma D Cancer Gene Ther; 2011 Nov; 18(11):825-36. PubMed ID: 21852812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]